-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
The Shenzhen Municipal Guiding Fund Investment Co., Ltd. (“Municipal Guiding Fund”), Shenzhen Longgang Financial Investment Holding Co., Ltd. (“Longgang Financial Holdings”), and Shenzhen Projimed Pharmaceutical Technology Co., Ltd. (“Shenzhen Projimed”) held a signing ceremony for the Shenzhen Projimed Injection-Grade Recombinant Human Serum Albumin Project.
Published Time:
2019-05-06 18:16
2017 On the afternoon of December 14, Shenzhen Guiding Fund Investment Co., Ltd. (hereinafter referred to as "Shenzhen Guiding Fund"), Longgang Financial Investment Holding Co., Ltd. (hereinafter referred to as "Longgang Financial Holdings"), and Shenzhen Probio Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shenzhen Probio") held a signing ceremony for the Shenzhen Probio Injection-Grade Recombinant Human Serum Albumin project. Shenzhen Guiding Fund and Longgang Financial Holdings invested 300 million yuan and 150 million yuan, respectively, in Shenzhen Probio to accelerate the project's implementation in Longgang. Longgang District leaders Zhang Yong, Chen Guangwen, and Zhang Jing, and Jiang Yucai, general manager of Shenzhen Guiding Fund, attended the signing ceremony.
Probio's injection-grade recombinant human serum albumin research and development project was selected as a major new drug creation project during the 13th Five-Year Plan period. The project leader is Luo Yongzhang, director of the State Key Laboratory of Anti-tumor Protein Drugs and professor at Tsinghua University. The project's technical team mainly comes from the State Key Laboratory of Anti-tumor Protein Drugs, which possesses a number of core technologies and key processes and has first-class capabilities in industrial-academic-research transformation.
Probio's controlling shareholder, Beijing Probio, mainly engages in the development and production of recombinant protein drugs, antibody drugs, and in vitro diagnostic reagents. It has established a research and development and large-scale preparation platform for recombinant protein drugs, and its recombinant protein drug research and development technology is internationally leading. It has successively undertaken numerous national and provincial and ministerial key projects such as major new drug creation and the 863 Program. It has 58 domestic and international invention patents and other achievements such as the key technology research and development of injection-grade recombinant human serum albumin.
Shenzhen and Longgang District attach great importance to the introduction and implementation of this project. The municipal government meeting approved an investment of 300 million yuan by the Shenzhen Guiding Fund in Shenzhen Probio; and Longgang Financial Holdings, which manages the Longgang District Guiding Fund, invested 150 million yuan to increase its stake in Shenzhen Probio.
Related Recommendations
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC